Johnson & Johnson (JNJ)

130.87
2.28 1.71
NYSE : Health Technology
Prev Close 133.15
Open 132.75
Day Low/High 130.66 / 133.45
52 Wk Low/High 118.05 / 148.32
Volume 6.55M
Avg Volume 7.19M
Exchange NYSE
Shares Outstanding 2.69B
Market Cap 349.97B
P/E Ratio 22.72
Div & Yield 3.36 (2.53%)

Latest News

JNJ INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Investigation On Behalf Of Johnson & Johnson Investors

JNJ INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Investigation On Behalf Of Johnson & Johnson Investors

Law Offices of Howard G. Smith continues its investigation on behalf of Johnson & Johnson Investors ("J&J" or the "Company") (NYSE:  JNJ) investors concerning the Company and its officers' possible violations...

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Jim Cramer says it's extremely important to buy stocks that are exactly right for you and your level of risk tolerance.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Johnson & Johnson

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Johnson & Johnson

The Klein Law Firm announces the commencement of an investigation of Johnson & Johnson (NYSE: JNJ) concerning possible violations of federal securities laws.

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

We could be poised for even a further advance PROVIDED that we stay oversold.

Glancy Prongay & Murray LLP Continues Investigation On Behalf Of Johnson & Johnson Investors (JNJ)

Glancy Prongay & Murray LLP Continues Investigation On Behalf Of Johnson & Johnson Investors (JNJ)

Glancy Prongay & Murray LLP ("GPM") continues its investigation on behalf of Johnson & Johnson ("J&J" or the "Company") (NYSE:  JNJ) investors concerning the Company and its officers' possible...

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Johnson & Johnson

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Johnson & Johnson

The Klein Law Firm announces the commencement of an investigation of Johnson & Johnson (NYSE: JNJ) concerning possible violations of federal securities laws.

Scott+Scott, Attorneys At Law, LLP Alerts Investors To The Filing Of A Securities Class Action Against Johnson & Johnson (JNJ)

Scott+Scott, Attorneys At Law, LLP Alerts Investors To The Filing Of A Securities Class Action Against Johnson & Johnson (JNJ)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Johnson & Johnson (NYSE: JNJ)...

JNJ SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Johnson & Johnson

JNJ SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Johnson & Johnson

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Johnson & Johnson ("Johnson & Johnson" or the "Company") (NYSE: JNJ) violated federal securities laws.

The Decline In Johnson & Johnson Could Be Close to Being Over

The Decline In Johnson & Johnson Could Be Close to Being Over

How do the charts look now and is it safe to consider being a buyer again?

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report

A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.

JNJ LOSS NOTICE: Rosen Law Firm Reminds Johnson & Johnson Investors Of Important Deadline In First Filed Case

JNJ LOSS NOTICE: Rosen Law Firm Reminds Johnson & Johnson Investors Of Important Deadline In First Filed Case

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Johnson & Johnson (NYSE: JNJ) between February 22, 2013 and February 7, 2018, both dates inclusive ("Class Period") of the...

JNJ SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Johnson & Johnson

JNJ SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Johnson & Johnson

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Johnson & Johnson ("Johnson & Johnson" or the "Company") (NYSE: JNJ) violated federal securities laws.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Johnson & Johnson -- JNJ

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Johnson & Johnson -- JNJ

Levi & Korsinsky announces it has commenced an investigation of Johnson & Johnson (NYSE:JNJ) ("Johnson & Johnson" or the "Company") concerning possible violations of federal securities laws.

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

As lawsuits tied to the opioid crisis keep piling up, Purdue Pharma is discontinuing direct sales calls to doctors. Will other opioid makers follow suit?

Jim's Daily Rundown

Jim discusses our First Data Corp exit, his interview with Broadcom's CEO, Nvidia, and his Real Money article from earlier today.

These 5 Dow Stocks Are Already in Correction in 2018

These 5 Dow Stocks Are Already in Correction in 2018

There are five stocks in the Dow that have entered correction territory.

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Jim Cramer highlights Roku, Amazon, Teladoc, Weyerhaeuser, Mondelez International, Mazor Robotics, and Kratos Defense & Security.

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Jim Cramer tackles the volatility issue and outlines the game plan for next week.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Johnson & Johnson

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Johnson & Johnson

Levi & Korsinsky announces it has commenced an investigation of Johnson & Johnson (NYSE:JNJ) ("Johnson & Johnson" or the "Company") concerning possible violations of federal securities laws.

Rosen Law Firm Files Securities Class Action Lawsuit Against Johnson & Johnson

Rosen Law Firm Files Securities Class Action Lawsuit Against Johnson & Johnson

Rosen Law Firm, a global investor rights law firm, today announced it has filed a federal securities class action lawsuit on behalf of purchasers of the securities of Johnson & Johnson (NYSE:JNJ) between Feb.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback

3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback

Large-cap healthcare stocks, especially those in the medical technology sector, are one of the biggest losers in the recent market selloff.

TheStreet Quant Rating: A (Buy)